Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine and Bromhexine for COVID-19 Prophylaxis
NCT04340349Phase 1Unknown
- Sponsor
- Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra
- Start
- Feb 2021
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Hydroxychloroquine + Bromhexine with Placebo (2 arms). Primary endpoint: Quantification of the expression of mRNA SARS-CoV-2 and presence or absence of antibodies anti-SARS-CoV-2 at 60 days. Status: unknown.
02
Drugs
hydroxychloroquinebromhexine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04340349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04340349.